BCAT1 Inhibitor Therapy for AML Subtype Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective strategies for identifying and treating subtypes of Acute Myeloid Leukemia (AML) characterized by increased BCAT1 expression, particularly in patients with IDHwtTETwt, where high BCAT1 levels are associated with shorter overall survival.
Innovation Solution
A compound that increases intracellular α-ketoglutarate levels, such as BCAT1 inhibitors or α-ketoglutaric acid derivatives, is administered to treat AML patients with BCAT1high expression and IDHwtTETwt, along with a method for stratifying patients based on BCAT1 and IDH/TET genotype to tailor drug regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If BCAT1 expression is increased in AML cells, then cell proliferation and tumorigenesis are promoted, but intracellular α-ketoglutarate levels decrease
Solution Approach 1:
The patent converts the harmful effect of BCAT1 overexpression (depleting α-ketoglutarate) into a beneficial therapeutic target. By identifying that BCAT1 inhibition restores α-ketoglutarate levels and activates anti-tumorigenic pathways, the invention transforms the metabolic vulnerability created by BCAT1 overexpression into a therapeutic opportunity for AML treatment
Solution Approach 2:
The patent changes the metabolic parameter of α-ketoglutarate levels by inhibiting BCAT1 enzyme activity. This parameter change restores the balance of α-ketoglutarate in the cell, thereby reactivating αKG-dependent dioxygenases and anti-tumorigenic pathways that were suppressed by BCAT1 overexpression
2Reliability
If AML patients are stratified by BCAT1 expression status and IDH/TET genotype, then treatment efficacy is improved, but diagnostic complexity increases
Solution Approach 1:
The patent segments AML patients into distinct molecular subtypes based on BCAT1 expression status and IDH/TET genotype. This segmentation allows for tailored treatment approaches, where BCAT1-inhibiting compounds are specifically applied to BCAT1high IDHwtTETwt patients, thereby improving treatment efficacy while providing clear diagnostic criteria for each subtype
3Object-affected harmful factors
If BCAT1 inhibitors are used to increase α-ketoglutarate levels, then anti-tumorigenic pathways are activated, but off-target effects on normal metabolism may occur
Solution Approach 1:
The patent applies BCAT1 inhibition selectively to AML cells with high BCAT1 expression, exploiting the local metabolic vulnerability of cancer cells rather than affecting normal cells with baseline BCAT1 levels. This localized approach activates anti-tumorigenic pathways in cancer cells while minimizing off-target effects on normal metabolism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach potentially improves prognosis by targeting AML subtypes with elevated BCAT1 expression, increasing α-ketoglutarate levels to inhibit tumorigenic pathways, thereby enhancing treatment efficacy and overall survival.
Implementation Method 1
BCAT1 transfers the α-amino group from the essential BCAAs valine, leucine or isoleucine to α-ketoglutarate (αKG)
Implementation Method 2
αKG, which next to its role in the tricarboxylic acid (TCA) cycle is an essential co-factor for αKG-dependent dioxygenases such as EGLN1 or TET family of DNA demethylases
Data Source
AI summary
This invention relates to a novel approach for the identification and stratification of subtypes of cancer, particularly subtypes of cancer characterized by an increased expression of BCAT1, particularly Acute Myeloid Leukemia (AML). The invention furthermore relates to a novel approach with respect to the treatment of cancer, particularly subtypes of cancer characterized by an increased expression of BCAT1, particularly Acute Myeloid Leukemia (AML).